

Accepted Manuscript

STAT3 mediates Nilotinib response in KIT-altered Melanoma: a Phase II Multicenter Trial of the French Skin Cancer Network

Julie Delyon, Sylvie Chevret, Thomas Jouary, Sophie Dalac, Stephane Dalle, Bernard Guillot, Jean-Philippe Arnault, Marie-Françoise Avril, Christophe Bedane, Guido Bens, Anne Pham-Ledard, Sandrine Mansard, Florent Grange, Laurent Machet, Nicolas Meyer, Delphine Legoupil, Philippe Saiag, Zakia Idir, Victor Renault, Jean-François Deleuze, Elif Hindie, Maxime Battistella, Nicolas Dumaz, Samia Mourah, Celeste Lebbe

PII: S0022-202X(17)32802-6

DOI: [10.1016/j.jid.2017.07.839](https://doi.org/10.1016/j.jid.2017.07.839)

Reference: JID 1019

To appear in: *The Journal of Investigative Dermatology*

Received Date: 29 March 2017

Revised Date: 18 June 2017

Accepted Date: 14 July 2017

Please cite this article as: Delyon J, Chevret S, Jouary T, Dalac S, Dalle S, Guillot B, Arnault J-P, Avril M-F, Bedane C, Bens G, Pham-Ledard A, Mansard S, Grange F, Machet L, Meyer N, Legoupil D, Saiag P, Idir Z, Renault V, Deleuze J-F, Hindie E, Battistella M, Dumaz N, Mourah S, Lebbe C, and the GCC (French Group of Skin Cancer), STAT3 mediates Nilotinib response in KIT-altered Melanoma: a Phase II Multicenter Trial of the French Skin Cancer Network, *The Journal of Investigative Dermatology* (2017), doi: 10.1016/j.jid.2017.07.839.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ORIGINAL ARTICLE

STAT3 mediates Nilotinib response in KIT-altered Melanoma: a Phase II Multicenter Trial of the French Skin Cancer Network

Julie DELYON^{1,2,3}, Sylvie CHEVRET^{3,4}, Thomas JOUARY⁵, Sophie DALAC⁶, Stephane DALLE⁷, Bernard GUILLOT⁸, Jean-Philippe ARNAULT⁹, Marie-Françoise AVRIL¹⁰, Christophe BEDANE¹¹, Guido BENS¹², Anne PHAM-LEDARD¹³, Sandrine MANSARD¹⁴, Florent GRANGE¹⁵, Laurent MACHET¹⁶, Nicolas MEYER¹⁷, Delphine LEGOUPIL¹⁸, Philippe SAIAG¹⁹, Zakia IDIR²⁰, Victor RENAULT²¹, Jean-François DELEUZE²², Elif HINDIE²³, Maxime BATTISTELLA²⁴, Nicolas DUMAZ^{*2}, Samia MOURAH^{*2,3,25}, Celeste LEBBE^{*1,2,3}, ; and the GCC (French Group of Skin Cancer).

* equally contributing authors

¹ Service de Dermatologie, and CIC (Centre d'Investigations Cliniques), AP-HP, Hôpital Saint-Louis, Paris, France

² INSERM, UMR-976, Hôpital Saint-Louis, Paris, France

³ Université Paris Diderot, Sorbonne Paris Cité, Paris, France

⁴ Service de Biostatistique et Information Médicale, AP-HP, Hôpital Saint-Louis, Paris, France

⁵ Unité Onco-dermatologie, Hôpital François Mitterrand, 4 Bd Hauterive, 64000 Pau, France.

⁶ Service de Dermatologie, CHU Dijon Bourgogne, Dijon, France

⁷ Cancer Research Center of Lyon - INSERM U1052 - CNRS UMR5286, Claude Bernard Lyon 1 University, Institut de Cancérologie des Hospices Civils de Lyon, France

⁸ Montpellier University Hospital F34095 Montpellier, France

⁹ Service de Dermatologie, CHU Amiens-Picardie, 80054 Amiens cedex 1, France

¹⁰ AP-HP, Hôpital Cochin, Service de Dermatologie, Paris, France ; Université Paris Descartes

¹¹ Unité d'oncologie thoracique et cutanée, Hopital Dupuytren, 2 avenue Martin Luther king, 87042 Limoges

Download English Version:

<https://daneshyari.com/en/article/8716230>

Download Persian Version:

<https://daneshyari.com/article/8716230>

[Daneshyari.com](https://daneshyari.com)